Literature DB >> 28798833

Implications of prostate-specific antigen screening guidelines on clinical practice at a Canadian regional community hospital.

Todd M Webster1, Erika Lau2, Ken J Newell2.   

Abstract

Entities:  

Year:  2017        PMID： 28798833      PMCID： PMC5542840          DOI： 10.5489/cuaj.4140

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  14 in total

Review 1.  Pathologic assessment of the surgical specimen.

Authors:  J I Epstein
Journal:  Urol Clin North Am       Date:  2001-08       Impact factor: 2.241

2.  Recommendations on screening for prostate cancer with the prostate-specific antigen test.

Authors:  Neil Bell; Sarah Connor Gorber; Amanda Shane; Michel Joffres; Harminder Singh; James Dickinson; Elizabeth Shaw; Lesley Dunfield; Marcello Tonelli
Journal:  CMAJ       Date:  2014-10-27       Impact factor: 8.262

3.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

4.  Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Authors:  Fritz H Schröder; Jonas Hugosson; Sigrid Carlsson; Teuvo Tammela; Liisa Määttänen; Anssi Auvinen; Maciej Kwiatkowski; Franz Recker; Monique J Roobol
Journal:  Eur Urol       Date:  2012-06-07       Impact factor: 20.096

5.  National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.

Authors:  Michael W Drazer; Dezheng Huo; Scott E Eggener
Journal:  J Clin Oncol       Date:  2015-06-08       Impact factor: 44.544

6.  Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.

Authors:  Bimal Bhindi; Muhammad Mamdani; Girish S Kulkarni; Antonio Finelli; Robert J Hamilton; John Trachtenberg; Alexandre R Zlotta; Andrew Evans; Theodorus H van der Kwast; Ants Toi; Neil E Fleshner
Journal:  J Urol       Date:  2014-12-03       Impact factor: 7.450

Review 7.  The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation.

Authors:  Mahul B Amin; Daniel W Lin; John L Gore; John R Srigley; Hema Samaratunga; Lars Egevad; Mark Rubin; John Nacey; H Ballentine Carter; Laurence Klotz; Howard Sandler; Anthony L Zietman; Stuart Holden; Rodolfo Montironi; Peter A Humphrey; Andrew J Evans; Jonathan I Epstein; Brett Delahunt; Jesse K McKenney; Dan Berney; Thomas M Wheeler; Arul M Chinnaiyan; Lawrence True; Beatrice Knudsen; M Elizabeth H Hammond
Journal:  Arch Pathol Lab Med       Date:  2014-08-05       Impact factor: 5.534

8.  Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.

Authors:  Ahmedin Jemal; Stacey A Fedewa; Jiemin Ma; Rebecca Siegel; Chun Chieh Lin; Otis Brawley; Elizabeth M Ward
Journal:  JAMA       Date:  2015-11-17       Impact factor: 56.272

9.  Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.

Authors:  Joshua A Cohn; Chihsiung E Wang; Justin C Lakeman; Jonathan C Silverstein; Charles B Brendler; Kristian R Novakovic; Michael S McGuire; Brian T Helfand
Journal:  Urol Oncol       Date:  2013-08-02       Impact factor: 3.498

10.  Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

Authors:  W J Catalona; J P Richie; J B deKernion; F R Ahmann; T L Ratliff; B L Dalkin; L R Kavoussi; M T MacFarlane; P C Southwick
Journal:  J Urol       Date:  1994-12       Impact factor: 7.450
View more
  3 in total

1.  PSA screening: Time to overcome our brand confusion.

Authors:  D Robert Siemens; Martin Gleave
Journal:  Can Urol Assoc J       Date:  2017-10       Impact factor: 1.862

2.  Changes in the uptake of screening for prostate cancer with prostate-specific antigen in Ontario between 2003 to 2012.

Authors:  Louis Watson
Journal:  Can Oncol Nurs J       Date:  2020-04-01

3.  Changements dans les pratiques de dépistage de l'antigène prostatique spécifique en Ontario entre 2003 et 2012.

Authors:  Louis Watson
Journal:  Can Oncol Nurs J       Date:  2020-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.